Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FEI Acquires VSG

By Drug Discovery Trends Editor | August 1, 2012

FEI, a leading instrumentation company providing imaging and analysis systems for research and industry, announced that it has acquired Visualization Sciences Group (VSG) of Bordeaux, France. VSG provides high-performance 3D visualization software products and tools to a range of markets, including oil & gas, geosciences, mining, life sciences, materials science and industrial inspection.

“VSG is an extension and acceleration of our strategy to provide complete imaging and visualization solutions to our customers,” said Don Kania, president and CEO of FEI. “Their products and development capabilities fit well with all of our target markets, especially in our higher-growth Natural Resources and Life Sciences businesses. Our customers are expressing an increasing demand for analysis of the data our imaging systems create. At the same time, FEI intends to continue to build upon VSG’s growing software business. We are impressed with VSG’s solutions, including state-of-the-art 3D rendering, an open application framework, object-oriented 3D libraries and very large 3D data management capabilities. The company has a strong management team and a talented group of employees.”

“Combining with FEI gives us added breadth and distribution capabilities to continue our growth,” commented Jean-Bernard Cazeaux, president and CEO of VSG. “We look forward to further contributing to FEI’s success in high-growth opportunities where we have a solid customer base, such as Life Sciences and Natural Resources, and to contributing our expertise to applications across all of FEI’s markets.”

The purchase price for the acquisition is EURO44.8 million or approximately $55 million. FEI funded the purchase with euros from its European operations which otherwise would be subject to U.S. taxation if repatriated. VSG had pro-forma revenue for the 12 months ended June 30, 2012 of approximately $19 million and has 88 employees. FEI expects the acquisition to have a neutral impact on GAAP earnings for the second half of 2012 and to be accretive in 2013.

Date: August 1, 2012
Source: FEI


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE